Study guide

European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management

Key Takeaways Explain This Topic AI

Preschool wheeze may occur only with viral infections or also between episodes and with other triggers. These patterns can change and do not establish airway inflammation or prognosis. Assess interval symptoms, atopy, severity and exacerbation history when deciding on an inhaled corticosteroid trial.

ICS-containing treatment is the foundation of childhood asthma control. BTS/NICE/SIGN starts children aged 5–11 on low-dose ICS plus as-needed SABA; MART is an option when uncontrolled and the child can use it correctly. Check product and national licensing, adherence and technique before stepping up or referring.

Montelukast is a possible oral add-on, including for exercise-related symptoms, but is less effective than ICS as preschool maintenance treatment and does not reliably prevent severe viral-wheeze attacks. Review a treatment trial and stop if ineffective. Warn caregivers about neuropsychiatric reactions and use an age-appropriate formulation.

Use a pMDI with spacer in young children, adding a snug face mask when they cannot seal around a mouthpiece. Move to a mouthpiece as soon as the child can use it, commonly around 4–5 years. A suitable DPI may be used in school-age children who demonstrate adequate inspiratory technique; reassess technique regularly.

Acute severe asthma (SpO2 <92%, heart rate >140 in young children, inability to talk) requires immediate high-flow oxygen, inhaled salbutamol via spacer or oxygen-driven nebulization, nebulized ipratropium bromide, early oral prednisolone (1–2 mg/kg, max 40 mg), and intravenous magnesium sulfate (40 mg/kg over 20 minutes) for refractory severe exacerbations.

Last updated: November 2026

Preschool Wheezing Phenotypes (<5 Years)

Wheezing affects approximately one in three children before their third birthday. In preschool children, confirm that the reported sound is wheeze, assess alternative diagnoses, and review symptom frequency and severity over time.

Clinical Patterns of Preschool Wheeze

Episodic viral wheeze and multiple-trigger wheeze are useful historical descriptions of symptom patterns. The ERS 2024 statement cautions that these labels alone do not identify airway pathology or predict treatment response:

Clinical Parameter Episodic Viral Wheeze Multiple-Trigger Wheeze

Definition Wheezing during discrete viral respiratory infections Wheezing during infections and with interval symptoms or other triggers

Inter-Episode Symptoms Well between infections, without persistent cough or exercise limitation Symptoms may occur with exercise, laughter, crying, allergens or smoke

Atopic Assessment Atopy may be present or absent; its absence does not exclude asthma or an ICS response Atopy increases the likelihood of allergic asthma but is not required

Underlying Inflammation Cannot be inferred from the viral-only pattern Cannot be inferred from the trigger pattern alone

Long-Term Course Many improve, but persistence and later asthma remain possible Persistent symptoms warrant reassessment; the label does not establish an individual prognosis

Initial Management As-needed inhaled salbutamol via pMDI and spacer may suffice for mild, infrequent episodes; reassess control and severe-episode history Consider a daily low-dose ICS trial , with as-needed salbutamol, after assessing symptoms, severity and alternative diagnoses

Note

Review treatment need rather than relying on the phenotype label. BTS/NICE/SIGN recommends an 8–12-week low-dose ICS trial for under-5s with interval symptoms suggesting maintenance treatment or severe episodes, such as hospital admission or two or more oral-steroid courses. Check technique and adherence, then assess response and whether treatment remains necessary.

Chronic Asthma Pathophysiology and Objective Assessment in School-Age Children (≥5 Years)

Childhood asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness, mucosal edema, Th2-mediated inflammation, and variable, reversible airflow obstruction.

Pathophysiological Cascade

In sensitized children, allergen exposure triggers dendritic cell presentation to naive T helper cells, inducing differentiation into Th2 lymphocytes . These cells release signature cytokines:

Interleukin-4 (IL-4) and Interleukin-13 (IL-13): Drive B-cell immunoglobulin class switching to immunoglobulin E (IgE) . IgE binds high-affinity FcεRI receptors on tissue mast cells and basophils.

Interleukin-5 (IL-5): Promotes bone marrow maturation, migration, activation, and survival of eosinophils .

Upon allergen cross-linking, mast cells degranulate, releasing histamine, cysteinyl leukotrienes (LTC4, LTD4, LTE4), and prostaglandin D2, causing immediate smooth muscle contraction, microvascular leakage, and thick mucus production.

Ongoing inflammation induces airway structural remodeling, including subepithelial basement membrane thickening, smooth muscle hypertrophy, and goblet cell hyperplasia.

Objective Diagnostic Testing

BTS/SIGN and European guidelines emphasize that asthma is a clinical diagnosis supported by objective demonstrations of variable expiratory airflow limitation :

Spirometry: In children typically aged 5 to 7 years and older who can perform reproducible forced expirations:

Obstructive Pattern: Reduced forced expiratory volume in 1 second ( F E V 1 FEV_1 FE V 1 ​ ) relative to forced vital capacity ( F V C FVC F V C ), defined by an F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C ratio below the lower limit of normal (typically <0.80 in children).

Bronchodilator Reversibility (BDR): An increase in F E V 1 FEV_1 FE V 1 ​ of ≥12% (or ≥200 mL ) after administering 400 mcg of inhaled salbutamol via spacer confirms significant, reversible airflow obstruction.

Fractional Exhaled Nitric Oxide (FeNO): Nitric oxide is synthesized by inducible nitric oxide synthase (iNOS) in respiratory epithelial cells in response to IL-4 and IL-13.

A FeNO concentration of ≥35 parts per billion (ppb) in symptomatic children supports the diagnosis of eosinophilic airway inflammation and predicts positive responsiveness to inhaled corticosteroids.

Stepwise Long-Term Pharmacological Management

Aim for normal activity, good symptom control and few exacerbations using the lowest effective treatment. Check diagnosis, adherence, inhaler technique and exposures before stepping up. The following is the BTS/NICE/SIGN pathway for ages 5–11 ; under-5 and adolescent pathways differ. [Initial treatment: Low-dose ICS twice daily + SABA as needed]

  • |
  • v
  • [If uncontrolled: Can the child manage MART correctly?]
  • Yes: Low-dose ICS-formoterol MART -> Moderate-dose MART if needed
  • No: Trial LTRA for 8-12 weeks; stop if ineffective
  • > Low-dose ICS/LABA + SABA -> Moderate-dose ICS/LABA + SABA
  • |
  • v
  • [Uncontrolled on moderate-dose MART or ICS/LABA]
  • Refer to a specialist in paediatric asthma
  • Specialist reassessment before high-dose therapy or phenotype-specific biologics
  • Controller Selection and Review

Initial Maintenance: Prescribe twice-daily low-dose ICS plus as-needed salbutamol. Dose bands depend on drug, device and guideline: GINA's examples for ages 6–11 include budesonide 100–200 mcg/day or fluticasone propionate 50–100 mcg/day. Check the selected product rather than assuming equal microgram potency. Established school-age asthma requires ICS-containing treatment; SABA alone does not treat inflammation.

MART Pathway: If uncontrolled on low-dose ICS and able to manage the regimen, consider low-dose ICS-formoterol MART , increasing to moderate-dose MART if needed. The same inhaler provides maintenance and relief because formoterol acts rapidly; an ICS-salmeterol inhaler cannot serve this purpose. MART reduces exacerbations in appropriate children. Licensing varies: the UK November 2025 update identifies one budesonide-formoterol 100/6 mcg dry-powder product licensed for MART at 6–11 years ; other products under 12 may be off-label. It is not universally approved from age 4.

Conventional Pathway: If the child cannot manage MART, consider an 8–12-week LTRA trial with low-dose ICS and SABA; stop the LTRA if ineffective. If still uncontrolled, use a low-dose fixed ICS/LABA inhaler plus SABA, then moderate-dose ICS/LABA if necessary. An effective LTRA may be continued. Never prescribe LABA without ICS.

Specialist Assessment: Refer if uncontrolled on moderate-dose MART or moderate-dose ICS/LABA, with or without an effective LTRA. Reassess diagnosis, technique, adherence and exposures before further escalation. Specialists may consider high-dose therapy, tiotropium or age- and phenotype-appropriate biologics such as omalizumab, mepolizumab or dupilumab. Review response after treatment changes and step down when sustained control permits.

Leukotriene Receptor Antagonists: Clinical Role and Neuropsychiatric Warnings

Montelukast: An oral cysteinyl leukotriene receptor-1 antagonist, usually taken once each evening: 4 mg granules at 6 months–<2 years; 4 mg chewable or granules at 2–5 years; 5 mg at 6–14 years; 10 mg at ≥15 years . It may help selected persistent or exercise-related symptoms. Review an add-on trial after 8–12 weeks and stop if ineffective. Daily ICS is more effective for preschool maintenance, and LTRA does not reliably reduce viral-wheeze exacerbations needing oral steroids.

Safety Advisory: European Medicines Agency (EMA) and UK MHRA black box alerts highlight the risk of neuropsychiatric adverse events . Prescribers must proactively warn parents regarding sleep disturbances, nightmares, aggression, irritability, depression, anxiety, and suicidal ideation. If neuropsychiatric symptoms occur, montelukast must be discontinued immediately.

Inhaler Delivery Systems, Spacer Mechanics, and Age-Appropriate Selection

Prescribing the correct inhaler device and verifying proper inhalation technique is as important as the choice of drug molecule. Poor inhalation technique is the leading cause of apparent treatment failure in pediatric asthma.

Age / Ability Recommended Device Administration Technique

Young child unable to use a mouthpiece pMDI with valved spacer and snug face mask , usually ages 0–3 Seal over nose and mouth; discharge 1 puff at a time and allow approximately 5 tidal breaths per puff

Child able to seal around a mouthpiece , often ages 4–5 onward pMDI with valved spacer and mouthpiece Seal lips around the mouthpiece; give 1 puff at a time and breathe slowly through the chamber

School-age child with demonstrated device ability pMDI with spacer , or an appropriately licensed DPI or breath-actuated device A DPI requires a fast, forceful, deep inspiration sufficient for that device. Check performance; retain pMDI/spacer access for attacks when inspiratory flow may be inadequate

Tip

THE CARDINAL RULES OF SPACER ADMINISTRATION:

Never discharge multiple puffs into a spacer simultaneously; multiple actuations can markedly reduce the amount of medication available for inhalation.

Avoid crying during administration. Crying is an entirely expiratory event followed by rapid, shallow breaths; virtually zero aerosol reaches the lower airways.

Wash spacers in warm water with mild detergent and allow to air-dry without wiping ; towel drying generates static electricity that traps medication particles on the plastic walls.

Emergency Stratification: Moderate, Severe, and Life-Threatening Asthma

When a child presents with an acute asthma exacerbation, immediate clinical categorization drives the escalation of acute resuscitation:

Clinical Parameter Mild / Moderate Exacerbation Acute Severe Asthma Life-Threatening Asthma

Speech & Feeding Talks in sentences; feeds well Cannot complete sentences in one breath; feeding compromised Unable to talk; too breathless to swallow

Oxygen Saturation (SpO2) ≥92% on room air <92% on room air <92% despite high-flow oxygen, or cyanosis

Heart Rate ≤140 bpm (2–5 yr); ≤125 bpm (>5 yr) >140 bpm (2–5 yr); >125 bpm (>5 yr) Bradycardia , irregular rhythm, hypotension

Respiratory Rate ≤40 bpm (2–5 yr); ≤30 bpm (>5 yr) >40 bpm (2–5 yr); >30 bpm (>5 yr) Feeble respiratory effort, exhaustion

Accessory Muscle Use Mild subcostal indrawing Marked sternal tug, scalene use, chest indrawing Paradoxical thoracoabdominal breathing

Auscultation Expiratory wheeze throughout Loud, diffuse biphasic wheezing "Silent chest" (insufficient airflow to generate wheeze)

Mental Status Alert, normal responsiveness Agitated, distressed, irritable Confused, lethargic, drowsy, comatose

  • Peak Flow (PEF) ≥50% of best or predicted 33% to 50% of best or predicted <33% of best or predicted
  • Acute Resuscitation Bundle for Pediatric Asthma [Initial Assessment: Severe / Life-Threatening]
  • High-Flow Oxygen via Reservoir Mask (Target SpO2 94-98%)
  • |
  • v
  • [First-Line Inhaled Bronchodilator Therapy]
  • Salbutamol: 10 puffs via pMDI + spacer OR 2.5-5 mg oxygen-driven nebulizer
  • Add: Ipratropium Bromide (250 mcg nebulized) every 20-30 min for the first hour
  • |
  • v
  • [Early Systemic Corticosteroids]
  • Oral Prednisolone 1-2 mg/kg (max 40 mg) OR IV Hydrocortisone 4 mg/kg
  • |
  • v
  • [If Refractory to First-Hour Inhaled Therapy / Life-Threatening]
  • IV Magnesium Sulfate: 40 mg/kg (max 2 g) IV infusion over 20 minutes
  • |
  • v
  • [PICU Escalation for Ongoing Deterioration]
  • IV Salbutamol Infusion (1-5 mcg/kg/min) + Continuous ECG monitoring

- IV Aminophylline: 5 mg/kg loading; usual infusion 1 mg/kg/hr under 12, 0.5-0.7 mg/kg/hr at 12-17; follow local critical-care protocol

- Closely monitored non-invasive support when appropriate -> Experienced paediatric airway team if respiratory failure develops

1. Oxygen Delivery

Administer high-flow humidified oxygen via a tight-fitting non-rebreather reservoir face mask (10–15 L/min flow) to achieve and maintain target SpO2 between 94% and 98% .

2. Inhaled Short-Acting Beta-2 Agonist (Salbutamol)

Moderate Exacerbation: Administer salbutamol 100 mcg via pMDI and spacer: 2 to 10 puffs , delivering 1 puff every 30 to 60 seconds with 5 tidal breaths per puff. Reassess after 20 to 30 minutes.

Severe / Life-Threatening Exacerbation: Administer continuous or frequent salbutamol:

pMDI + Spacer: 10 puffs repeated every 20 to 30 minutes.

Nebulization: Driven by 6 L/min medical oxygen (never compressed air, to avoid worsening hypoxemia). Dose: 2.5 mg for children younger than 5 years; 5.0 mg for children aged 5 years and older. Can be given back-to-back every 20 minutes or as continuous nebulization (5–10 mg/hour).

3. Inhaled Anticholinergic (Ipratropium Bromide)

Nebulized ipratropium bromide (250 micrograms) added to salbutamol every 20 to 30 minutes for the first hour of treatment in acute severe or life-threatening asthma.

Blocks muscarinic M3 receptors, eliminating vagal bronchomotor tone and inhibiting mucus hypersecretion. The combination produces synergistic bronchodilation and significantly lowers hospital admission rates.

4. Early Systemic Corticosteroids

Administer as early as possible within the first hour of presentation; clinical anti-inflammatory effects emerge within 2 to 4 hours.

Oral Route (Preferred): Oral prednisolone 1 to 2 mg/kg (maximum 40 mg in preschool/school-age children; up to 50 mg in adolescents) once daily for 3 to 5 days . Routine tapering of steroids is completely unnecessary for courses under 7 days.

Intravenous Route: Reserved for children unable to swallow, vomiting profusely, or in life-threatening exhaustion: IV hydrocortisone 4 mg/kg every 6 hours (maximum 100 mg per dose).

5. Second-Line Intravenous Therapies for Refractory Severe Asthma

If the child fails to improve after 1 hour of aggressive inhaled bronchodilators and systemic steroids, or exhibits immediate life-threatening features, initiate intravenous therapy without delay:

Intravenous Magnesium Sulfate:

Dosing: 40 mg/kg (maximum 2.0 grams) administered as an intravenous infusion in 100 mL of 0.9% normal saline over 20 minutes .

Mechanism: Potent physiological calcium channel blocker; inhibits calcium influx into bronchial smooth muscle cells, blocks acetylcholine release at motor nerve terminals, and suppresses histamine degranulation from mast cells.

Safety: Exceptionally safe; adverse effects are rare, including transient facial flushing, mild hypotension, and nausea. Monitor continuous heart rate and blood pressure.

Intravenous Salbutamol Infusion:

Dosing: IV bolus of 15 micrograms/kg (max 250 mcg) over 10 minutes, followed by a continuous infusion of 1 to 5 micrograms/kg/min (titrated to clinical response and heart rate).

Precautions: Monitor ECG, potassium, glucose and lactate. Beta-2 stimulation can cause tachycardia, intracellular potassium shifting and lactic acidosis , with compensatory tachypnea that can mimic worsening bronchospasm. Reassess perfusion, oxygenation and other causes such as hypovolemia or sepsis; do not automatically attribute a raised lactate to the drug. Review beta-agonist dosing if toxicity is suspected.

Intravenous Aminophylline:

Dosing: Load 5 mg/kg (max 500 mg) over 20–30 minutes; omit if already taking oral theophylline. A usual UK critical-care infusion is 1 mg/kg/hour below 12 years and 0.5–0.7 mg/kg/hour at 12–17 years , adjusted to response and concentrations under the local protocol.

Monitoring: This phosphodiesterase inhibitor has a narrow therapeutic index. Monitor ECG, electrolytes and clinical response. Follow the local theophylline-level protocol; many services check at 4–6 hours and then daily once stable (usual target 10–20 mg/L ). Toxicity can cause serious arrhythmias and seizures.

Caution

CRITICAL HAZARDS OF INTUBATING PEDIATRIC ASTHMA: Endotracheal intubation in status asthmaticus carries high morbidity and mortality from dynamic hyperinflation, severe intrinsic PEEP (auto-PEEP), barotrauma (tension pneumothorax, pneumomediastinum), and sudden circulatory collapse from impaired venous return. Obtain urgent expert airway/PICU help for exhaustion, deteriorating consciousness or ventilation, refractory hypoxemia, or respiratory arrest; do not wait for coma or arrest. An experienced paediatric airway team should perform intubation, commonly using ketamine and rocuronium, then allow prolonged expiratory times to limit air trapping.